Endpoints News 生物医药· Ryan Cross·· 2 天前AI 评分47
Priavoid 阿尔茨海默药 PRI-002 Phase 2 研究失败
#CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’s
AI 导读
德国生物科技公司 Priavoid 针对阿尔茨海默病开发的口服淀粉样蛋白解聚药物 PRI-002,其 Phase 2 临床试验未能达到预期目标。来源为 Endpoints News 对 #CTAD26 会议的报道,正文其余内容受付费墙限制未能完整显示。
正文
BOSTON — For nearly a decade, the German biotech startup Priavoid has been working on a pill to break up small clumps of amyloid proteins that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news